Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.08.2017 | original article | Ausgabe 15-16/2017

Wiener klinische Wochenschrift 15-16/2017

Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 15-16/2017
Autoren:
Xiuying Li, Jinfan Sun, Shuenqin Hu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi: 10.​1007/​s00508-017-1173-3) contains supplementary material, which is available to authorized users.

Summary

Background

It has been shown that caveolin-1 plays a potential role as a diagnostic and prognostic biomarker in various cancer types. The aim of the present study was to clarify whether caveolin-1 expressed in the breast cancer stroma could be a prognostic factor for breast cancer patients.

Methods

We searched the PubMed, ScienceDirect and Web of Science databases for published literature investigating associations between stromal caveolin-1 expression and survival outcome in breast cancer patients. With respect to survival outcomes, the pooled hazard ratios (HRs) of caveolin-1 and the 95% confidence intervals (CI) were calculated.

Results

Our meta-analysis identified a total of 10 studies involving 2072 cases. Further investigation demonstrated that a lack of caveolin-1 expression in the breast cancer stroma is a hazard for overall survival (OS) (HR = 2.33, 95% CI: 1.57–3.46) and disease-free/progression-free survival (DFS/PFS) (HR = 3.05, 95% CI: 2.26–4.12) in breast cancer patients. Moreover, lack of caveolin-1 expression in the cancer-associated fibroblasts was a significant predictor of DFS/PFS (HR = 2.79, 95% CI: 1.75–4.46).

Conclusion

Our results indicated that lack of expression of caveolin-1 in the breast cancer stroma is associated with a poor prognosis.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Zusatzmaterial
Supplementary Figure S1. Sensitivity analysis for OS, the expression of caveolin-1 in the tumor stroma
508_2017_1173_MOESM1_ESM.tif
Supplementary Figure S2. Sensitivity analysis for disease-free/progression-free survival (DFS/PFS), the expression of caveolin-1 in the tumor stroma
508_2017_1173_MOESM2_ESM.tif
Supplementary Figure S3. Sensitivity analysis for OS, the expression of caveolin-1 in the cancer-associated fibroblasts
508_2017_1173_MOESM3_ESM.tif
Supplementary Figure S4. Sensitivity analysis for disease-free/progression-free survival (DFS/PFS), the expression of caveolin-1 in the cancer-associated fibroblasts
508_2017_1173_MOESM4_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 15-16/2017

Wiener klinische Wochenschrift 15-16/2017Zur Ausgabe

MUW researcher of the month

MUW researcher of the month